Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularizati… Read more
Xbrane Biopharma AB (XBRANE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.121x
Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has a cash flow conversion efficiency ratio of -0.121x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-67.56 Million) by net assets (Skr560.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xbrane Biopharma AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Xbrane Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Xbrane Biopharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xbrane Biopharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SynCore Biotechnology Co Ltd
TWO:4192
|
-0.028x |
|
Dr. Phone Fix Canada Corporation
V:DPF
|
N/A |
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
0.242x |
|
AnorTech Inc.
V:ANOR
|
N/A |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
-1.143x |
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
-0.092x |
|
Beyond Air Inc
NASDAQ:XAIR
|
-0.509x |
|
Iconic Worldwide Bhd
KLSE:9113
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Xbrane Biopharma AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Xbrane Biopharma AB from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr560.65 Million | Skr-250.69 Million | -0.447x | +30.27% |
| 2024-12-31 | Skr208.54 Million | Skr-133.73 Million | -0.641x | +72.98% |
| 2023-12-31 | Skr171.34 Million | Skr-406.68 Million | -2.374x | -420.07% |
| 2022-12-31 | Skr424.89 Million | Skr-193.92 Million | -0.456x | +10.27% |
| 2021-12-31 | Skr431.74 Million | Skr-219.61 Million | -0.509x | +45.02% |
| 2020-12-31 | Skr257.71 Million | Skr-238.41 Million | -0.925x | -14.76% |
| 2019-12-31 | Skr184.32 Million | Skr-148.59 Million | -0.806x | -243.37% |
| 2018-12-31 | Skr83.07 Million | Skr46.71 Million | 0.562x | +234.89% |
| 2017-12-31 | Skr88.41 Million | Skr-36.85 Million | -0.417x | -13.44% |
| 2016-12-31 | Skr107.30 Million | Skr-39.43 Million | -0.367x | -40.93% |
| 2015-12-31 | Skr47.51 Million | Skr-12.39 Million | -0.261x | +38.46% |
| 2014-12-31 | Skr6.30 Million | Skr-2.67 Million | -0.424x | -67.55% |
| 2013-12-31 | Skr8.69 Million | Skr-2.20 Million | -0.253x | -- |